Zhangqiang Xiang, Mupeng Li, Shaoting Cui, Chunyan Gan, Fangfang Liu, Qian Huang, Gang Mai, Lianlian Fan
{"title":"Bioequivalence study of voriconazole for intravenous infusion in healthy Chinese subjects under fasting conditions.","authors":"Zhangqiang Xiang, Mupeng Li, Shaoting Cui, Chunyan Gan, Fangfang Liu, Qian Huang, Gang Mai, Lianlian Fan","doi":"10.1016/j.xphs.2024.12.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Voriconazole, a second-generation triazole, is used to prevent and treat invasive fungal infections. This study aimed to assess the bioequivalence and safety of test and reference voriconazole intravenous infusion under the fasting conditions.</p><p><strong>Methods: </strong>The study employed a randomized, open-label, single-dose, two-period, crossover trial design. Eligible subjects randomly assigned for screening, receiving either the test or reference voriconazole for intravenous infusion during the first period, with alternative products administered during the second period. The washout period lasted 7 days. The single administration dosage was fixed at 6mg/kg. Nineteen blood samples were collected at pre-dose and up to 46 h post-dose for each subject. The validated LC-MS/MS method was used to determine the concentration of voriconazole in plasma.</p><p><strong>Results: </strong>Twenty-four subjects were enrolled in the study, comprising 20 males and 4 females. The primary pharmacokinetic parameters (mean ± SD) were as follows: C<sub>max</sub> was 4631.20±744.80 and 5008.09±1020.77 ng/mL, AUC<sub>0-t</sub> was 27121.07±12658.03 and 28674.08±13118.05 ng*h/mL, and AUC<sub>0-∞</sub> was 28056.10±14428.76 and 29616.29±14783.70 ng*h/mL for the test and reference formulations, respectively. The 90% confidence intervals of geometric mean ratios for C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-∞</sub> fell within the range of 80.00% to 125.00%. Both products were well tolerated and no serious adverse event was observed.</p><p><strong>Conclusion: </strong>The test and reference voriconazole intravenous infusion demonstrated bioequivalence and good tolerability.</p>","PeriodicalId":16741,"journal":{"name":"Journal of pharmaceutical sciences","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xphs.2024.12.012","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Voriconazole, a second-generation triazole, is used to prevent and treat invasive fungal infections. This study aimed to assess the bioequivalence and safety of test and reference voriconazole intravenous infusion under the fasting conditions.
Methods: The study employed a randomized, open-label, single-dose, two-period, crossover trial design. Eligible subjects randomly assigned for screening, receiving either the test or reference voriconazole for intravenous infusion during the first period, with alternative products administered during the second period. The washout period lasted 7 days. The single administration dosage was fixed at 6mg/kg. Nineteen blood samples were collected at pre-dose and up to 46 h post-dose for each subject. The validated LC-MS/MS method was used to determine the concentration of voriconazole in plasma.
Results: Twenty-four subjects were enrolled in the study, comprising 20 males and 4 females. The primary pharmacokinetic parameters (mean ± SD) were as follows: Cmax was 4631.20±744.80 and 5008.09±1020.77 ng/mL, AUC0-t was 27121.07±12658.03 and 28674.08±13118.05 ng*h/mL, and AUC0-∞ was 28056.10±14428.76 and 29616.29±14783.70 ng*h/mL for the test and reference formulations, respectively. The 90% confidence intervals of geometric mean ratios for Cmax, AUC0-t, and AUC0-∞ fell within the range of 80.00% to 125.00%. Both products were well tolerated and no serious adverse event was observed.
Conclusion: The test and reference voriconazole intravenous infusion demonstrated bioequivalence and good tolerability.
期刊介绍:
The Journal of Pharmaceutical Sciences will publish original research papers, original research notes, invited topical reviews (including Minireviews), and editorial commentary and news. The area of focus shall be concepts in basic pharmaceutical science and such topics as chemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability of drugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery.